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Abstract:  
Back ground:  Human Epidermal growth factor Receptor 2 (HER-2/neu) over expression in breast 
cancer is associated with poor outcome and decrease disease free survival (DFS). The aim of this 
study was to evaluate the over expression of HER2/neu among premenopausal and postmenopausal 
females presented with malignant palpable breast lumps to Radio Isotope Center Khartoum (RICK). 
Methods: The study was a case-control conducted among patients attending Radiation Isotopes 
Centre Khartoum (RICK). A total of 328 women were randomly selected. Data were collected by a 
pre coded, pre tested questionnaire. Tissue biopsies of breast lumps had been analyzed using 
immunohistochemical techniques for HERR-2/neu over expression and its relation to other 
prognostic factors was evaluated.  
Results: HER-2/neu + vein first pregnancy at ≥ 23 years, were 32 (41%) in the cases, 6 (35%) in 
the controls of premenopausal women, and 21(44%) in the cases, 5 (38%) in the controls of 
postmenopausal women. HER-2/neu + veexpression in relation to age at menarche ≤ 12 years was 
39 (51%) in the cases, 7(39%) in the controls of premenopausal women, and 36 (56%) in the cases, 
7 (45%) in the controls of postmenopausal women. HER-2/neu+ vein relation to Body Mass Index 
> 29 kg/m2 showed 7 (37%) in the cases, 2 (33%) in the controls of premenopausal women 
(x2=0.024), and 8(38%) in the cases, 2(40%) in the controls of postmenopausal women (x2= 
0.006). HER-2/neu+ veexpression in relation to history of abortion or miscarriage (ever) was found 
to be 21 (39%) in the cases, 4 (33%) in the controls of premenopausal women, and 18 (44%) in the 
cases, 3 (33%) in the controls among postmenopausal women. HER-2/neu+ veexpression in relation 
to the history of breast cancer in a first degree relatives was 3 (25%) in the cases, 1(50%) in the 
controls of premenopausal women, and 4 (22%) in the cases, 2 (28%) in the controls of 
postmenopausal women. HER-2/neu+ veexpression in relation to the use of oral contraceptives was 
3 (37%) in the cases, 1(50%) in the controls among premenopausal women, and 3 (27%) in the 
cases, 1 (50%) in the controls of postmenopausal women. 
Conclusion: The study confirmed an etiological association between HER2/neu+ve and HER2/neu 
– ve and age at first pregnancy ≥ 23 years, age of menarche at ≤ 12 years, abortion or miscarriage in 
premenopausal and postmenopausal Sudanese women, while an etiological association was 
confirmed between HER2/neu+ve and HER2/neu –ve, and BMI in premenopausal women, and the 
family history of cancer in pos menopausal women. 
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reast cancer is the commonest cancer 
in women; it is rising at a rate of 
approximately 2% per year in all 
population 1. 
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The number of annual deaths from breast 
cancer has remained about the same for the 
last 50 years, although the number of cases is 
increasing. This shows the benefits of early 
detection, which impacts survival 2. In Sudan, 
breast cancer accounts for 34.5% of all female 
cancers. There is an alarming high frequency 
of women presenting with advanced breast 
cancer to the Radiation Isotope Center 
Khartoum (RICK). 
B
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Human Epidermal growth factor Receptor2 
(HER2/neu), a protein receptor found on the 
surface of cells, is a key component in 
regulating cell growth. When the HERa gene 
(sometimes written HER2/neu) is altered, 
extra HER2 receptors may be produced. The 
HER2/neu oncogene, also known as c-erb-B2, 
c-neu or ERBB2, is located in chromosome 
17q11.2-12, encoding an EGFR- family like 
glycoprotein3. Its amplification, which is 
strongly correlated with protein over 
expression, occurs in about 15-43% of breast 
tumors. This over expression of HER2 causes 
increased cell growth and reproduction often 
resulting in more aggressive tumor cells. 
HER2 protein over expression affects 25% to 
30% of breast cancer patients4. Indeed, 
several studies have demonstrated that HER-
2/neu amplification represents a prognostic 
and predictive marker; its expression is 
associated with early disease recurrence, 
relative resistance to chemo- and / or 
hormone therapy and short survival5. In most 
studies, over expression of HER2 was 
associated with adverse prognosis 
independent of other prognostic factors, even 
when multivariate analysis was used for the 
outcome analysis6.  
The aim of this study was to evaluate the 
HER2/neu expression in malignant breast 
palpable lumps among pre-menopausal and 




Study design: This was a case-control study 
to evaluate the tumor marker (ER-PR- and 
HER-2/neu) over expression in malignant 
breast lumps of Sudanese females.  
Setting: The study was conducted in RICK, 
from January 2006 to August 2008. RICK, 
which is located in Khartoum, is the first 
Radio Isotope Center in the Sudan and 
receives patients from all over the country. 
Study population: Sudanese females 
attended RICK during the study period were 
enrolled in the study. Subjects were classified 
as pre and postmenopausal. If the menstrual 
cycles had ended naturally at least 12 months 
before the interview, surgery or radiation 
therapy at any age the subject was considered 
to be postmenopausal. Those who reported 
not having menstrual cycles for the last 10 
months were considered as premenopausal 
and were combined with premenopausal 
women. 
Sampling: 328 females were selected using 
convenience sampling. An age-stratified 
random sample of 100 women was used as a 
control group from screened patients who 
were free of Ca. breast. 
Data collection:  Personal interviews were 
conducted with each woman during her first 
visit to the center (both patients and controls) 
using a structured, pre coded, pre tested 
questionnaire. Anthropometric measurements 
(weight and height) were also taken. Biopsies 
were taken from the breast lumps of the 
selected patients. The biopsies were far from 
the tumor margins. The specimens were 
directly placed in neutral buffer formation and 
considered for histopathology and 
immunohistochemistry. 
Data analysis: Data were analyzed by Odds 
ratio and Chi-square, using SPSS version 13. 
 
Ethical considerations: The aim of the study 
was fully explained to the patients and 
controls.  A verbal consent to participate was 
obtained from the participant, and their right 
to withdraw from the study was explained to 
the patients. Respect and privacy of the 
participants were maintained throughout the 
study period. Ethical clearance was obtained 




HER-2/neu + vein first pregnancy at ≥ 23 
years, were 32 (41%) in the cases, 6 (35%) in 
the controls of premenopausal women (Odds 
ratio (OR) = 1.3, Chi-square(X2) =0.234), and 
21(44%) in the cases, 5 (38%) in the controls 
of postmenopausal women (Odds ratio = 1.24, 
Chi-square =0.138).  
HER-2/neu + veexpression in relation to age 
at menarche of 12 years was 39 (51%) in the 
cases, 7(39%) in the controls of 
premenopausal women ((The ORs was 1.61, 
Chi-square =1.25), and 36 (56%) in the cases, 
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7 (45%) in the controls of postmenopausal 
women (The ORs was 1.1, Chi-square =0.25).  
HER-2/neu+ vein relation to Body Mass 
Index > 29 kg/m2 showed 7 (37%) in the 
cases, 2 (33%) in the controls of 
premenopausal women (x2=0.024), and 
8(38%) in the cases, 2(40%) in the controls of 
postmenopausal women (x2= 0.006).  
HER-2/neu+ veexpression in relation to 
history of abortion or miscarriage (ever) was 
found to be 21 (39%) in the cases, 4 (33%) in 
the controls of premenopausal women, and 18 
(44%) in the cases, 3 (33%) in the controls 
among postmenopausal women.      
HER-2/neu+ veexpression in relation to the 
history of breast cancer in a first degree 
relatives was 3 (25%) in the cases, 1(50%) in 
the controls of premenopausal women, and 4 
(22%) in the cases, 2 (28%) in the controls of 
postmenopausal women. 
 
HER-2/neu+ veexpression in relation to the 
use of oral contraceptives was 3 (37%) in the 
cases, 1(50%) in the controls among 
premenopausal women, and 3 (27%) in the 
cases, 1 (50%) in the controls of 
postmenopausal women (Table1).
 
Table (1): Relation between HER-2/neu over expression and risk factors among pre and post-













Age at first 
pregnancy ≥ 23  : 
     Cases 







OR = 1.30 







OR = 1.24 
X2=0.138 Not Sig. 
Age of menarche      
(≤ 12 years) 
             Cases 







OR (95% CI):1.61 







OR (95% CI): 1.10 
X2: 0.25  Not Sig. 
BMI:      
             Cases 





OR = 1.17 





OR = 0.92 
X2=0.006  Not Sig.
Abortion/miscarriage: 
           Cases 





OR (95% CI):1.27 





OR (95% CI): 1.43 
X2: 0.92 Not Sig. 
Family history of Ca. 
         Cases 





OR (95% CI):0.84 





OR (95% CI): 1.11 
X2: 0.096Not Sig.  
oral contraceptives: 
           Cases 





OR (95% CI):0.80 





OR (95% CI): 0.86 
X2: 0.18 – Not Sig. 
 
Discussion: 
In contrast with other investigators7 who have 
shown an elevated risk for HER-2/neu+ve 
tumors with an early age at first full 
pregnancy, we found an elevated risk with a 
late  age   regardless  of   HER-2/neu   protein  
expression, but the comparison between 
 
HER-2/neu+ve and HER-2/neu-ve tumors 
revealed an association with HER-2/neu+ve 
breast cancers. The relation between HER-
2/neu +ve in the first pregnancy at ≥ 23 years 
in the cases and controls was not significant 
in pre and postmenopausal women. 
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Obesity was related to breast cancer in post 
menopausal females whom cancer cells over 
express HER-2/neu oncoprotein. In fact 
increase BMI elevated the risk in both groups 
but the comparison between HER-2/neu+ 
veand HER-2/neu- tumors revealed a much 
stronger association with HER-2/neu+ 
vebreast cancers. The comparison between 
Estrogen Receptors ER+ and ER – tumors 
revealed a much stronger association with ER 
+ breast cancers. 
Few studies have examined the possibility 
whether HER-2/neu status can help to 
discriminate etiologically between distinct 
subgroups of breast cancer cases, and none of 
them has identified the effect of increased 
BMI to HER-2/neu positive tumors8-11. 
Previous findings10, 11 suggested an inverse 
relationship between abortion and HER-
2/neu+ vebreast cancers, while we also found 
this inverse association but independently of 
HER-2/neu status. Interestingly, abortion 
increased the risk for HER-2/neu+ vetumors 
only in the premenopausal women.  
More specifically, compared to investigators7 
who have shown an elevated risk for HER-
2/neu+ vetumors with an early age at 
menarche, we found also, an elevated risk 
with an early age regardless of HER-2/neu 
protein expression. The comparison between 
HER-2/neu+ veand HER-2/neu- tumors 
revealed a much stronger association with 
HER-2/neu+ vebreast cancers. These findings 
were in agreement with previous reports11. 
We found that previous family history of 
cancer was related to postmenopausal breast 
tumors that over express HER-2/neu+ve. 
While previous family history of cancer was 
related with premenopausal breast tumors that 
were HER-2/neu-ve. These findings were in 
agreement with Vlachonikolis IG  et al11.  
Early use of contraceptives has been 
positively associated with HER-2/neu+ 
vebreast cancer7, 12, but our findings were 
different, revealing a positive association with 
HER-2/neu-ve tumors. However, because the 
number of oral contraceptive and hormone 
replacement therapy (HRT) users in this study 
was small, this subgroup analysis was 
hindered by decreased power to detect 
associations of any magnitude.  
Our findings have similarities and differences 
with respect to previous reports that examined 
the associations of breast risk factors with 
HER-2/neu status. This inconsistency may 
reflect differences in study design, 
individuals, and laboratory methodology. In 
this study we used immunochemistry (CB11 
monoclonal antibody) to assess the HER-
2/neu protein over expression, which is highly 
correlated with gene amplification according 
to previous reports. Also, the percentage of 
women with breast cancer and HER-2/neu 
protein over expression found here was within 





The study confirmed an etiological 
association between HER2/neu+ and 
HER2/neu – and age at first pregnancy ≥ 23 
years, age of menarche at ≤ 12 years, abortion 
or miscarriage in both premenopausal and 
postmenopausal Sudanese women, while an 
etiological association was confirmed 
between HER2/neu+ and HER2/neu –, and 
BMI in premenopausal women, and the 
family history of cancer in postmenopausal 
women. The study did not reveal an 
etiological association between HER-2/ neu 
and use of oral contraceptive in pre and 
postmenopausal women. As a result of this 
study, statistical significance was not 
confirmed between HER2/neu+ and 
HER2/neu –, and age at first pregnancy ≥ 23 
years, age of menarche at ≤ 12 years, abortion 
or miscarriage, BMI, family history of cancer 
and use of oral contraceptive in pre and 
postmenopausal women. HER2/neu 
immunohistochemistry can be used as a 
reliable indicator of the presence of mutated 
nuclear HER2/neu protein. Whether this 
method can be performed reliably in clinical 
practice may need further studies. The value 
of HER2/neu as a prognostic indicator, and its 
correlation with other prognostic factors 
needs further investigation as well. 
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